Recent advances in anogenital antiretroviral microbicides and multimodal delivery systems

Journal of AIDS and Clinical Research

Volumn 3, Issue 3, 2012, Pages

  D'Cruz, Osmond J ^a   Uckun, Fatih M ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AIDS; Human Immunodeficiency Virus 1; Microbicide; Receptive anal intercourse; Rectal; Reverse transcriptase; Vaginal

Indexed keywords

EID: 84879829750     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000144     Document Type: Review

References (415)

1. Global report 2010. Geneva: UNAIDS
2. Virginia Department of Health. The impact of HIV/AIDS among black women in Virginia. VDH: Division of Disease Prevention (HIV, STD, TB RX) August 2006.
3. Samuel MC, Hessol N, Shiboski S, Engel RR, Speed TP, et al. (1993) Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984-89. J Acquir Immune Defic Syndr 6: 303-312.
4. Buchbinder SP, Douglas JM Jr, McKirnan DJ, Judson FN, Katz MH, et al. (1996) Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior. J Infect Dis 174: 954-961.
5. Padian NS, Shiboski SC, Glass SO, Vittinghoff E (1997) Heterosexual transmission of Human Immunodeficiency Virus (HIV) in Northern California: results from a ten-year study. Am J Epidemiol 146: 350-357.
6. Seidlin M, Vogler M, Lee E, Lee YS, Dubin N (1993) Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS 7: 1247-1254.
7. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, et al. (1999) Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 150: 306-311.
8. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, et al. (2001) Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149-1153.
9. Gorbach PM, Manhart LE, Hess KL, Stoner BP, Martin DH, et al. (2009) Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the United States. Sex Transm Dis 36: 193-198.
10. Mosher WD, Chandra A, Jones J (2005) Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data 362: 1-55.
11. Misegades L, Page-Shafer K, Halperin D, McFarland W, YWS Study Investigators Group. Young Women's Survey (2001) Anal intercourse among young low-income women in California: an overlooked risk factor for HIV? AIDS 15: 534-535.
12. Karim SS, Ramjee G (1998) Anal sex and HIV transmission in women. Am J Public Health 88:1265-1266.
13. Lane T, Pettifor A, Pascoe S, Fiamma A, Rees H (2006) Heterosexual anal intercourse increases risk of HIV infection among young South African men. AIDS 20: 123-125.
14. Kalichman S, Simbayi LC, Cain D, Jooste S (2009) Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect 85: 411-415.
15. Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, et al. (2000) Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 14: 85-88.
16. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, et al. (2008) SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3: e1474.
17. Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, et al. (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359: 463-472.
18. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372: 1977-1987.
19. Abdool Karim S, Coletti A, Richardson B, Ramjee G, Hoffman IF, et al. (2011) HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of vaginal microbicides Buffer gel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. AIDS 25: 957-966.
20. Hladik F, McElrath MJ (2008) Setting the stage: host invasion by HIV. Nat Rev Immunol 8: 447-457.
21. Hladik F, Hope TJ (2009) HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 6: 20-28.
22. Haase AT (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
23. Haase AT (2011) Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 62: 127-139.
24. Caffrey M (2011) HIV envelope: challenges and opportunities for development of entry inhibitors. Trends Microbiol 19: 191-197.
25. Doms RW, Moore JP (2000) HIV-1 membrane fusion: targets of opportunity. J Cell Biol 151: F9-14.
26. Kilby JM, Eron JJ (2003) Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 348: 2228-2238.
27. Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15: 690-698.
28. Lewinski MK, Bushman FD (2005) Bushman. Retroviral DNA integration-mechanism and consequences. Adv Genet 55: 147-181.
29. Cherepanov P, Maertens GN, Hare S (2011) Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol 21: 249-256.
30. Adamson CS, Freed EO (2007) Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol 55: 347-487.
31. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, et al. (2009) Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog 5: e1000437.
32. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921-926.
33. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, et al. (2008) Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135: 49-60.
34. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, et al. (2008) Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4: 495-504.
35. Davis CW, Doms RW (2004) HIV transmission: closing all the doors. J Exp Med 199: 1037-1040.
36. Borrow P, Shattock RJ, Vyakarnam A; EUROPRISE Working Group (2010) Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology 7: 84.
37. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105: 7552-7557.
38. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206: 1273-1289.
39. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, et al. (2000) Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 74: 5577-5586.
40. Bouschbacher M, Bomsel M, Verronèse E, Gofflo S, Ganor Y, et al. (2008) Early events in HIV transmission through a human reconstructed vaginal mucosa. AIDS 22: 1257-1266.
41. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, et al. (2007) Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci USA 104: 19464-19469.
42. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, et al. (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26: 257-270.
43. Keele BF, Estes JD (2011) Barriers to mucosal transmission of immunodeficiency viruses. Blood 118: 839-846.
44. Cole AM (2006) Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 306: 199-230.
45. Hickey DK, Patel MV, Fahey JV, Wira CR (2011) Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 88: 185-194.
46. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, et al. (2004) Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 71: 761-769.
47. Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, et al. (2003) Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 17: F39-48.
48. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, et al. (2005) Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 79: 14318-14329.
49. Pollakis G, Stax MJ, Paxton WA (2011) Innate immune factors associated with HIV-1 transmission. Curr Opin HIV AIDS 6: 341-347.
50. Lehner T, Wang Y, Whittall T, Seidl T (2011) Innate immunity and HIV-1 infection. Adv Dent Res 23: 19-22.
51. Weber J, Desai K, Darbyshire J; Microbicides Development Programme (2005) The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med 2: e142.
52. Catalone BJ, Kish-Catalone TM, Neely EB, Budgeon LR, Ferguson ML, et al. (2005). Comparative safety evaluation of candidate vaginal microbicide C31G. Antimicrob Agents Chemother 49: 1509-1520.
53. Osborn L, Kunkel S, Nabel GJ (1989) Tumor necrosis factor alpha and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of nuclear factor kappa B. Proc Natl Acad Sci U S A 86: 2336-2340.
54. Febo IL, Beauchamp B (2011) Prevention Overview: Role of Microbicides in Preventing HIV Infection. HIV Care Link 12: 1-3
55. Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, et al. (2003) Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17: 321-329.
56. Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, et al. (2004) A randomized phase I vaginal safety study of three concentrations of C31G vs. extra strength Gynol II. Contraception 70: 233-240.
57. Van der Straten A, Napierala S, Cheng H, Mauck C, Depineres T, et al. (2007) A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe. Contraception 76: 389-399.
58. Van de Wijgert JH, Braunstein SL, Morar NS, Jones HE, Madurai L, et al. (2007) Carraguard vaginal gel safety in HIV-positive women and men in South Africa. J Acquir Immune Defic Syndr 46: 538-546.
59. Hemelaar J, Gouws E, Ghys PD, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
60. Thomson MM, Najera R (2007) Increasing HIV-1 genetic diversity in Europe. J Infect Dis 196: 1120-1124.
61. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, et al. (2003) Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 77: 1021-1038.
62. Hemelaar J, Gouws E, Ghys PD, Osmanov S (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-23.
63. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, et al. (2007) Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 59: 517-524.
64. Kantor R, Katzenstein D (2003) Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 5: 25-35.
65. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, et al. (2006) HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20: F9-13.
66. Onafuwa-Nuga A, Telesnitsky A (2009) The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev 73: 451-480.
67. D'Cruz OJ, Uckun FM (2004) Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 10: 315-336.
68. D'Cruz OJ, Uckun FM (2006) Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 57: 411-423.
69. Klasse PJ, Shattock R, Moore JP (2008) Antiretroviral drug based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 59: 455-471.
70. D'Cruz OJ, Uckun FM (2006) Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res 4: 329-345.
71. Kenney J, Aravantinou M, Singer R, Hsu M, Rodriguez A, et al. (2011) An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 6: e15835.
72. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, et al. (2009) Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 83: 10358-10365.
73. D'Cruz OJ, Waurzyniak B, Uckun FM (2004) Antiretroviral spermicide WHI-07 prevents vaginal and rectal transmission of feline immunodeficiency virus in domestic cats. Antimicrob Agents Chemother 48: 1082-1088.
74. D'Cruz OJ, Uckun FM (2002) Pre-clinical safety evaluation of novel nucleoside analogue-based dual-function microbicides (WHI-05 and WHI-07). J Antimicrob Chemother 50: 793-803.
75. D'Cruz OJ, Uckun FM (2008) Microbicides for multidrug-resistant and multitropic HIV-1. Curr Opin Investig Drugs 9: 152-169.
76. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, et al. (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280: 1949-1953.
77. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, et al. (1998) CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 72: 4694-4703.
78. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, et al. (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
79. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. (1996) The betachemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148.
80. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. (1996) Identification of a major coreceptor for primary isolates of HIV-1. Nature 381: 661-666.
81. Margolis L, Shattock R (2006) Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 4: 312-317.
82. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, et al. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIVsuppressive factors produced by CD8+ T cells. Science 270: 1811-1815.
83. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-725.
84. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, et al. (1997) Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 3: 23-36.
85. Duma L, Häussinger D, Rogowski M, Lusso P, Grzesiek S (2007) Recognition of RANTES by extracellular parts of the CCR5 receptor. J Mol Biol 365: 1063-1075.
86. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, et al. (2004) Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306: 485-487.
87. Veazey RS, Ling B, Green LC, Ribka EP, Lifson JD, et al. (2009) Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 199: 1525-1527.
88. Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, et al. (2010) Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 202: 739-744.
89. Vangelista L, Secchi M, Liu X, Bachi A, Jia L, et al. (2010) Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrob Agents Chemother 54: 2994-3001.
90. Secchi M, Xu Q, Lusso P, Vangelista L (2009) The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants. Protein Expr Purif 68: 34-41.
91. Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, et al. (2005) J The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 79: 11179-11186.
92. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, et al. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80: 4909-4920.
93. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, et al. (2009) Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PloS One 4: e5683.
94. Westby M, van der Ryst E (2010) CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir Chem Chemother 20: 179-192.
95. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, et al. (2007) HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361: 212-228.
96. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, et al. (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81: 2359-2371.
97. Hartley O, Gaertner H, Wilken J, Thompson D, Fish R, et al. (2004) Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci U S A 101: 16460-16465.
98. Polo S, Nardese V, De Santis C, Arcelloni C, Paroni R, et al. (2000) Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur J Immunol 30: 3190-3198.
99. Vangelista L, Secchi M, Lusso P (2008) Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 26: 3008-3015.
100. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, et al. (2002) Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 99: 16249-16254.
101. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, et al. (2004) Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 78: 5476-5485.
102. Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, et al. (2000) Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol 74: 4868-4876.
103. Labrosse B, Labernardière JL, Dam E, Trouplin V, Skrabal K, et al. (2003) Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 77: 1610-1613.
104. Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, et al. (2002) Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 161: 867-873.
105. Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, et al. (2005) Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 79: 7121-7134.
106. Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, et al. (1988) Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 62: 2107-2114.
107. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, et al. (2008) Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol 375: 969-978.
108. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
109. Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS (2010) Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 88: 107-115.
110. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
111. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
112. Allen TM, Lopes de Menezes D, Hansen CB, Moase EH (1998) Stealth™ liposomes for the targeting of drugs in cancer therapy, McC. Gregoriadis, Editor, Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems, Plenum, New York, 61-75.
113. Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA (2010) Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob Agents Chemother 54: 2753-2766.
114. Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, et al. (2003) Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18: 27-39.
115. Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, et al. (2007) Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol 81: 395-405.
116. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433.
117. de Parseval A, Bobardt MD, Chatterji A, Chatterji U, Elder JH, et al. (2005) A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J Biol Chem 280: 39493-39504.
118. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071.
119. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/ human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347.
120. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/ SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
121. Abdel-Motal UM, Sarkis PT, Han T, Pudney J, Anderson DJ, et al. (2011) Antigp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One 6: e26473.
122. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, et al. (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virusinactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 41: 1521-1530.
123. Bolmstedt AJ, O'Keefe BR, Shenoy SR, McMahon JB, Boyd MR (2001) Cyanovirin-N defines a new class of antiviral agent targeting N-linked, highmannose glycans in an oligosaccharide-specific manner. Mol Pharmacol 59: 949-954.
124. Ziółkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, et al. (2006) Domainswapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 14: 1127-1135.
125. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, et al. (2003) Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 19: 535-541.
126. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, et al. (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 20: 11-18.
127. Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, et al. (2006) Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 50: 3250-3259.
128. Huang X, Jin W, Griffin GE, Shattock RJ, Hu Q (2011) Removal of two highmannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin. J Gen Virol 92: 2367-2373.
129. Balzarini J, Van Laethem K, Peumans WJ, Van Damme EJ, Bolmstedt A, et al. (2006) Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80: 8411-8421.
130. Huskens D, Vermeire K, Vandemeulebroucke E, Balzarini J, Schols D (2008) Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 40: 2802-2814.
131. Huskens D, Férir G, Vermeire K, Kehr JC, Balzarini J, et al. (2010) Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem 285: 24845-24854.
132. Witvrouw M, Fikkert V, Hantson A, Pannecouque C, O'keefe BR, et al. (2005) Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol 79: 7777-7784.
133. Hu Q, Mahmood N, Shattock RJ (2007) High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368: 145-154.
134. Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, et al. (2002) Retrocyclin: a primate peptide that protects cells from infection by T-and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A 99: 1813-1818.
135. Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, et al. (2004) RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses 20: 1157-1165.
136. Cole AM, Patton DL, Rohan LC, Cole AL, Cosgrove-Sweeney Y, et al. (2010) The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One 5: e15111.
137. Cihlar T, Ray AS (2010) Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 85: 39-58.
138. Kearney BP, Flaherty JF, Shah J (2004) Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 43: 595-612.
139. De Clercq E (2011) The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. Biochem Pharmacol 82: 99-109.
140. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, et al. (2010) In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 5: e9310.
141. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194: 904-911.
142. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, et al. (2008) Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 5: e157.
143. García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5: e28.
144. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, et al. (2006) Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20: 543-551.
145. Schwartz JL, Poindexter A, Wheeless A, Mauck CK, Callahan MM (2009) Safety evaluation of 1% tenofovir gel in healthy men. Int J STD AIDS 20: 384-386.
146. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, et al. (2011) A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 6: e16475.
147. Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, et al. (2011) A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 6: e25974.
148. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
149. Microbicide Trial Network (2011) MTN statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women.
150. Microbicide Trial Network (2011) MTN statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women.
151. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, et al. (2011) Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med 3: 112re4.
152. Saumoy M, Vidal F, Peraire J, Sauleda S, Vea AM, et al. (2004) Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 18: 1741-1742.
153. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, et al. (2009) Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 89: 513-519.
154. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, et al. (2009) Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a crosssectional study. J Infect Dis 200: 1746-1754.
155. Jhaveri MA, Mawad HW, Thornton AC, Mullen NW, Greenberg RN (2010) Tenofovir-associated severe bone pain: I cannot walk! J Int Assoc Physicians AIDS Care (Chic) 9: 328-334.
156. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, et al. (2010) Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 394: 48-53.
157. Vigano A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, et al. (2007) Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 27: 573-581.
158. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, et al. (2011) Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 91: 852-858.
159. Miller MD, Margot N, Lu B, Zhong L, Chen SS, et al. (2004) Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 189: 837-846.
160. Das K, Bandwar RP, White KL, Feng JY, Sarafianos SG, et al. (2009) Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 284: 35092-35100.
161. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, et al. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477: 95-98.
162. White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, et al. (2004) Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 48: 992-1003.
163. von Wyl V, Yerly S, Boni J, Bürgisser P, Klimkait T, et al. (2008) Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis 46: 1299-1309.
164. Hachiya A, Kodama EN, Schuckmann MM, Kirby KA, Michailidis E, et al. (2011) K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One 6: e16242.
165. Hurt CB, Eron JJ Jr, Cohen MS (2011) Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Clin Infect Dis 53: 1265-1270.
166. Uckun FM (2006) Unmet challenges in HIV therapy and potential of stampidine. Arzneimittelforschung 56: 117-120.
167. Uckun FM, Cahn P, Qazi S, D'Cruz O (2012) Stampidine as a promising anti-retroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Expert Opin Investig Drugs.
168. Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, et al. (2007) Intracellular nucleoside trophosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antiviral Ther 12: 981-986.
169. Venkatachalam TK, Tai HL, Vig R, Chen CL, Jan ST, et al. (1998) Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. Bioorg Med Chem Lett 8: 3121-3126.
170. Uckun FM, Pendergrass S, Venkatachalam TK, Qazi S, Richman D (2002) Stampidine is a potent inhibitor of zidovudine and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical HIV-1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 46:3613-3616.
171. Uckun FM, Pendergrass S, Qazi S, Venkatachalam TK (2004) In vitro activity of stampidine against primary clinical HIV isolates. Arzneimittelforschung 54: 69-77.
172. Uckun FM, Qazi S, Venkatachalam TK (2005) In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung 55: 223-231.
173. Uckun FM, Venkatachalam TK, Qazi S (2006) Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Arzneimittelforschung 56: 193-203.
174. Uckun FM, DuMez D, Qazi S, Tibbles H, Venkatachalam TK (2007) Antiretroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Arzneimittelforschung 57: 112-121.
175. Chen CL, Venkatachalam TK, Zhu ZH, Uckun FM (2001) In vivo pharmacokinetics and metabolism of anti-HIV agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] in mice. Drug Metab Dispos 29: 1035-1041.
176. Chen CL, Yu G, Venkatachalam T, Uckun FM (2002) Metabolism of stavudine-5'-[p-bromophenyl methoxy alaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab Dispos 30: 1523-1531.
177. Uckun FM, Chen CL, Lisowski E, Mitcheltree GC, Venkatachalam TK, et al. (2003) Toxicity and pharmacokinetics of stampidine in mice and rats. Arzneimittelforschung 53: 357-367.
178. Uckun FM, Waurzyniak B, Tibbles H, Venkatachalam TK, Erbeck D (2006) In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats. Arzneimittelforschung 56: 176-192.
179. Uckun FM, Qazi S, Pendergrass S, Lisowski E, Waurzyniak B, et al. (2002) In vivo toxicity, pharmacokinetics, and anti-HIV activity of stavudine-5'-(p-bromo phenyl methoxyalaninyl phosphate) (stampidine) in mice. Antimicrob Agents Chemother 46: 3428-3436.
180. Uckun FM, Chen CL, Samuel P, Pendergrass S, Uckun FM, et al. (2003) In vivo antiretroviral activity of stampidine in chronically FIV-infected cats. Antimicrob Agents Chemother 47: 1233-1240.
181. D'Cruz OJ, Samuel P, Waurzyniak B, Uckun FM (2003) Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod 69: 1843-1851.
182. D'Cruz OJ, Uckun FM (2004) Stampidine is a potential nonspermicidal broadspectrum anti-human immunodeficiency virus microbicide. Fertil Steril 81: 831-841.
183. D'Cruz OJ, Uckun FM (2005) Stampidine: a selective oculo-genital microbicide. J Antimicrob Chemother 56: 10-19.
184. D'Cruz OJ, Uckun FM (2007) Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1. Fertil Steril 88: 1197-1206.
185. Cahn P, Rolon MJ, Gun AM, Ferrari I, Dibirdik I, et al. (2012) Preclinical and first-in-human Phase I clinical evaluation of Stampidine, a potent anti-HIV pharmaceutical drug candidate. J AIDS Clinic Res 3: 138.
186. Elinder M (2011) Towards a new generation of anti-HIV drugs. Interaction kinetic analysis of enzyme inhibitors using SPR-biosensors. Digital comprehensive summaries of Uppsala dissertations from the Faculty of Science and Technology 834, 61pp. Uppsala.
187. D'Cruz OJ, Uckun FM (2006) Novel tight binding PETT, HEPT and DABObased non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Enzyme Inhib Med Chem 21: 329-350.
188. Zussman A, Lara L, Lara HH, Bentwich Z, Borkow G (2003) Blocking of cellfree and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 17: 653-661.
189. Barnard J, Borkow G, Parniak MA (1997) The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36: 7786-7792.
190. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, et al. (1997) Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 71: 3023-3030.
191. Borkow G, Salomon H, Wainberg MA, Parniak MA (2002) Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res Hum Retroviruses 18: 711-714.
192. Hossain MM, Parniak MA (2006) In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTIresistant human immunodeficiency virus type 1. J Virol 80: 4440-4446.
193. D'Cruz OJ, Uckun FM (2005) Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide. Mol Hum Reprod 11: 767-777.
194. Pani A, Musiu C, Loi AG, Mai A, Loddo R, et al. (2001) DABOs as candidates to prevent mucosal HIV transmission. Antivir Chem Chemother 12: 51-59.
195. Motakis D, Parniak MA (2002) A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46: 1851-1856.
196. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, et al. (2004) In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 48: 337-339.
197. Selhorst P, Vazquez AC, Terrazas-Aranda K, Michiels J, Vereecken K, et al. (2011) Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother 55: 1403-1413.
198. Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, et al. (2010) Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 26: 1181-1190.
199. Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW (2010) Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 55: 161-169.
200. Romano J, Variano B, Coplan P, Van Roey J, Douville K, et al. (2009) Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 25: 483-488.
201. Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, et al. (2009) Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 23: 1531-1538.
202. Nel A, Smythe S, Young K, Malcolm K, McCoy C, et al. (2009) Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 51: 416-423.
203. Di Fabio S, Van Roey J, Giannini G, van den Mooter G, Spada M, et al. (2003) Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 17: 1597-1604.
204. Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, et al. (2009) Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 53: 487-495.
205. Terrazas-Aranda K, Van Herrewege Y, Lewi PJ, Van Roey J, Vanham G (2007) In vitro pre-and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. Antivir Chem Chemother 18: 141-151.
206. Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, et al. (2011) Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 55: 600-607.
207. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, et al. (2010) TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 54: 718-727.
208. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, et al. (2007) Efficacy and safety of TMC125 (etravirine) in 440 treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, doubleblind, placebo-controlled trial. Lancet 370: 29-38.
209. Wang J, Bambara RA, Demeter LM, Dykes C (2010) Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J Virol 84: 9377-9389.
210. Schader SM, Oliveira M, Ibanescu RI, Moisi D, Colby-Germinario SP, et al. (2011) The in vitro resistance profile of the candidate HIV-1 microbicide drug Dapivirine. Antimicrob Agents Chemother 56: 751-756.
211. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, et al. (1998) Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Bioorg Med Chem 6: 1789-1797.
212. Sudbeck EA, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlgren L, et al. (1998) Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 42: 3225-3233.
213. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM (1999) Rational design of N-[2-(2,5-dimethoxyphenyl ethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett 9: 1593-1598.
214. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM (1999) Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant HIV. Antivir Chem Chemother 10: 233-240.
215. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM (2000) Structure-based drug design of nonnucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol 60: 1251-1265.
216. Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, et al. (1999) N'-[2-(2-thiophene)ethyl[-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett 9: 3411-3416.
217. Uckun FM, Qazi S, Venkatachalam T (2007) N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)] thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity. Arzneimittelforschung 57: 278-285.
218. D'Cruz OJ, Qazi S, Yiv S, Uckun FM (2012) A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)] thiourea]). Expert Opin Investig Drugs 21: 265-279.
219. D'Cruz OJ, Samuel P, Uckun FM (2005) Conceival, a novel non-contraceptive vaginal vehicle for lipophilic microbicides. AAPSPharmsciTech 6: E56-64.
220. D'Cruz OJ, Samuel P, Uckun FM (2004) PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod 71: 2037-2047.
221. D'Cruz OJ, Erbeck D, Uckun FM (2005) A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate. Toxicol Pathol 33: 465-476.
222. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
223. Zamore PD, Tuschl T, Sharp PA, Bartel DP (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33.
224. Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 15: 188-200.
225. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, et al. (2002) siRNA-directed inhibition of HIV-1 infection. Nat Med 8: 681-686.
226. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, et al. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20: 500-505.
227. Jacque J, Triques K, Stevenson M (2002) Modulation of HIV-1 replication by RNA interference. Nature 418: 435-438.
228. Anderson J, Banerjea A, Akkina R (2003) Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 13: 303-312.
229. Coburn GA, Cullen BR (2002) Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 76: 9225-9231.
230. Song E, Lee SK, Dykxhoorn DM, Novina C, Zhang D, et al. (2003) Sustained small interfering RNAmediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 77: 7174-7181.
231. Butticaz C, Ciuffi A, Munoz M, Thomas J, Bridge A, et al. (2003) Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression. Antiviral Ther 8: 373-377.
232. Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ (2004) Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther 11: 1703-1712.
233. Anderson J, Akkina R (2005) CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology 2: 53.
234. Lee SK, Dykxhoorn DM, Kumar P, Ranjbar S, Song E, et al. (2005) Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 106: 818-826.
235. Anderson J, Akkina R (2007) Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther 14: 1287-1297.
236. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, et al. (2008) T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-586.
237. Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719.
238. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59: 75-86.
239. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B (2003) Human immunodeficiency virus type 1 escape from RNA interference. J Virol 77: 11531-11535.
240. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, et al. (2004) Human Immunodeficiency virus type 1 escapes from RNA interferencemediated inhibition. J Virol 78: 2601-2605.
241. Bunka DH, Platonova O, Stockley PG (2010) Development of aptamer therapeutics. Curr Opin Pharmacol 10: 557-562.
242. James W (2001) Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery. Curr Opin Pharmacol 1: 540-546.
243. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
244. Robertson DL, Joyce GF (1990) Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344: 467-468.
245. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
246. Khati M, Schüman M, Ibrahim J, Sattentau Q, Gordon S, et al. (2003) Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J Virol 77: 12692-12698.
247. Moore MD, Cookson J, Coventry VK, Sproat B, Rabe L, et al. (2011) Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J Biol Chem 286: 2526-2535.
248. McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, et al. (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 8: 1005-1015.
249. Zhou J, Li H, Li S, Zaia J, Rossi JJ (2008) Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 16: 1481-1489.
250. Zhou J, Swiderski P, Li H, Zhang J, Neff CP, et al. (2009) Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 3094-3109.
251. Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, et al. (2011) An aptamersiRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3: 66ra6.
252. Zhou J, Rossi JJ (2011) Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol Biol 721: 355-371.
253. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, et al. (2011) Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121: 2401-2412.
254. De Rosa G, La Rotonda MI (2009) Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules 14: 2801-2823.
255. Coetzee N, Blanchard K, Ellertson C, Hoosen A, Friedland B (2001) Acceptability and feasibility of Micralax applicators and of methylcellulose placebo for large-scale clinical trials of vaginal microbicides. AIDS 15: 1837-1842.
256. Whitehead SJ, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, et al. (2011) Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand. PLoS One 6: e14831.
257. Carballo-Diéguez A, Exner T, Dolezal C, Pickard R, Lin P, et al. (2007) Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis 34: 224-229.
258. Bergogne-Bérézin E, Bryskier A (1999) The suppository form of antibiotic administration: pharmacokinetics and clinical application. J Antimicrob Chemother 43: 177-1785.
259. Carballo-Diéguez A, Dolezal C, Bauermeister JA, O'Brien W, Ventuneac A, et al. (2008) Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect 84: 483-487.
260. Kelly CG, Shattock RJ (2011) Specific microbicides in the prevention of HIV infection. J Intern Med 270: 509-519.
261. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, et al. (1996) Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2: 767-775.
262. Hendrix CW, Cao YJ, Fuchs EJ (2009) Topical microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol 49: 349-375.
263. Acartürk F (2009) Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 3: 193-205.
264. Grabovac V, Guggi D, Bernkop-Schnürch A (2005) Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev 57: 1713-1723.
265. Herold BC, Mesquita PM, Madan RP, Keller MJ (2011) Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am J Reprod Immunol 65: 325-333.
266. Lard-Whiteford SL, Matecka D, O'Rear JJ, Yuen IS, Litterst C, et al. (2004) Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. J Acquir Immune Defic Syndr 36: 541-552.
267. Ramjee G, Kamali A, McCormack S (2010) The last decade of microbicide clinical trials in Africa: from hypothesis to facts. AIDS 24: S40-49.
268. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, et al. (2009) Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 200: 599-608.
269. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, et al. (1993) Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 7: 95-102.
270. Levine WC, Pope V, Bhoomkar A, Tambe P, Lewis JS, et al. (1998) Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 177: 167-174.
271. Rosenberg ZF, Nel A, Heyward W, Mitchnick M (2006) Microbicides for the prevention of HIV infection in women: an overview of recent trials. Curr Opin HIV AIDS 1: 514-519.
272. Shattock RJ, Moore JP (2003) Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 1: 25-34.
273. Stone A, Harrison PF (2010) Microbicides: Way forward. Alliance for Microbicide Development.
274. Patton DL, Sweeney YT, Balkus JE, Rohan LC, Moncla BJ, et al. (2007) Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother 51: 1608-1615.
275. Lapenta C, Boirivant M, Marini M, Santini SM, Logozzi M, et al. (1999) Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur J Immunol 29: 1202-1208.
276. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, et al. (2000) Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 14: 1761-1765.
277. Kilby JM (2001) Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues. Clin Infect Dis 33: 873-884.
278. Morrow G, Vachot L, Vagenas P, Robbiani M (2008) Current concepts of HIV transmission. Curr Infect Dis Rep 10: 133-139.
279. Shacklett BL, Anton PA (2010) HIV Infection and Gut Mucosal Immune Function: Updates on Pathogenesis with Implications for Management and Intervention. Curr Infect Dis Rep 12: 19-27.
280. Brenchley JM, Douek DC (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol 1: 23-30.
281. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360: 971-977.
282. McGowan I (2008) Rectal microbicides: a new focus for HIV prevention. Sex Transm Infect 84: 413-417.
283. Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, et al. (2011) First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One 6: e23243.
284. Bergogne-Bérézin E, Bryskier A (1999) The suppository form of antibiotic administration: pharmacokinetics and clinical application. J Antimicrob Chemother 43: 177-185.
285. Boily MC, Dimitrov D, Abdool Karim SS, Mâsse B (2011) The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. Sex Transm Infect 87: 646-653.
286. Carballo-Diéguez A, Exner T, Dolezal C, Pickard R, Lin P, et al. (2007) Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis 34: 224-229.
287. Louissaint NA, Nimmagadda S, Fuchs EJ, Bakshi RP, Cao YJ, et al. (2012) Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men. J Acquir Immune Defic Syndr 59: 10-17.
288. Kim YT, Shin BK, Garripelli VK, Kim JK, Davaa E, et al. (2010) A thermosensitive vaginal gel formulation with HPgammaCD for the pH-dependent release and solubilization of amphotericin B. Eur J Pharm Sci 41: 399-406.
289. McGowan I (2011) Rectal microbicides: can we make them and will people use them? AIDS Behav 15: S66-71.
290. Zhu T, Mo H, Wang N, Nam DS, Carr A, et al. (1993) Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261: 1179-1181.
291. Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, et al. (1996) Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 70: 3098-3107.
292. Jiang Y, Tian B, Saifuddin M, Agy MB, Emau P, et al. (2009) RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res Ther 6: 23.
293. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, et al. (2001) Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 75: 1990-1995.
294. Singer R, Derby N, Rodriguez A, Kizima L, Kenney J, et al. (2011) The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 85: 5504-5512.
295. Nuttall J, Kashuba A, Wang R, White N, Allen P, et al. (2012) Pharmacokinetics of Tenofovir following intravaginal and intrarectal administration of Tenofovir gel to rhesus macaques. Antimicrob Agents Chemother 56: 103-109.
296. CDC (2011) Pre-exposure prophyxaxis (PrEP) February 21.
297. AIDS Vaccine Advocacy Coalition. Global advocacy for HIV prevention. Ongoing PrEP trials.
298. Naswa S, Marfatia YS (2011) Pre-exposure prophylaxis of HIV. Indian J Sex Transm Dis 32: 1-8.
299. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
300. FHI 360: VOICE September 2011 Update: VOICE HIV prevention trial continues, but researchers suspend oral tenofovir arm because of futility (September 28, 2011).
301. FHI 360: VOICE Nevember 2011 update: VOICE HIV Prevention Trial Discontinues Tenofovir Gel Arm for Futility.
302. FHI 360: FEM-PrEP June 2011 Update: FEM-PrEP study will be highly unlikely to demonstrate Truvada's effectiveness in preventing HIV infection in the study population.
303. FHI 360: FEM-PrEP July 2011 Update: Partners PrEP and TDF2 pre-exposure prophylaxis trials both demonstrate effectiveness in preventing HIV infection among heterosexuals.
304. University of Washington Internation Clinical Research Center July 2011 Update: Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa.
305. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, et al. (2011) Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 66: 240-250.
306. Myers GM, Mayer KH (2011) Oral preexposure anti-HIV prophylaxis for highrisk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS 25: 63-71.
307. Jayaraman N (2009) Multivalent ligand presentation as a central concept to study intricate carbohydrate-protein interactions. Chem Soc Rev 38: 3463-3483.
308. Hillaireau H, Le Doan T, Couvreur P (2006) Polymer-based nanoparticles for the delivery of nucleoside analogues. J Nanosci Nanotechnol 6: 2608-2617.
309. Kabanov AV, Vinogradov SV (2009) Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Intern Ed 48: 5418-5429.
310. Vinogradov SV, Poluektova LY, Makarov E, Gerson T, Senanayake MT (2010) Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity. Antivir Chem Chemother 21: 1-14.
311. du Toit LC, Pillay V, Choonara YE (2010) Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/ AIDS. Adv Drug Deliv Rev 62: 532-546.
312. Kim PS, Read SW (2010) Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2: 693-702.
313. Mallipeddi R, Rohan LC (2010) Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv 7: 37-48.
314. Gunaseelan S, Gunaseelan K, Deshmukh M, Zhang X, Sinko PJ (2010) Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv Drug Deliv Rev 62: 518-531.
315. Bernkop-Schnurch A (2005) Mucoadhesive polymers: Strategies, achievements and future challenges. Adv Drug Deliv Rev 57: 1553-1555.
316. Smart JD (2005) The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 57: 1556-1568.
317. Valenta C (2005) The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 57: 1692-1712.
318. Serra L, Domenech J, Peppas NA (2009) Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur J Pharm Biopharm 71: 519-528.
319. Ojewole E, Mackraj I, Naidoo P, Govender T (2008) Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 70: 697-710.
320. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC (2009) Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 26: 502-511.
321. Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, et al. (2008) Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc 130: 6896-6897.
322. Nolting B, Yu JJ, Liu GY, Cho SJ, Kauzlarich S, et al. (2003) Synthesis of gold glyconanoparticles and biological evaluation of recombinant gp120 interactions. Langmuir 19: 6465-6473.
323. Lara HH, Ixtepan-Turrent L, Garza-Treviño EN, Rodriguez-Padilla C (2010) PVP-coated silver nanoparticles block the transmission of cell-free and cellassociated HIV-1 in human cervical culture. J Nanobiotechnology 8: 15.
324. Wang X, Ramstrom O, Yan M (2009) A photochemically initiated chemistry for coupling underivatized carbohydrates to gold nanoparticles. J Mater Chem 19: 8944-8949.
325. Bastian AR, Kantharaju, McFadden K, Duffy C, Rajagopal S, et al. (2011) Cellfree HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120. ChemMedChem 6: 1335-1339, 1318.
326. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, et al. (2005) Interaction of AgNPs with HIV-1. J Nanobiotechnology 3: 6.
327. Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C (2010) Mode of antiviral action of AgNPs against HIV-1. J Nanobiotechnology 8: 1.
328. Lara HH, Ixtepan-Turrent L, Garza Treviño EN, Singh DK (2011) Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins. J Nanobiotechnology 9: 38.
329. McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, et al. (2005) Dendrimers as drugs: Discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2: 312-318.
330. Rupp R, Rosenthal SL, Stanberry LR (2007) VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2: 561-566.
331. Tyssen D, Henderson SA, Johnson A, Sterjovski J, Moore K, et al. (2010) Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One 5: e12309.
332. Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL (2006) Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 50: 1696-1700.
333. Jiang YH, Emau P, Cairns JS, Flanary L, Morton WR, et al. (2005) SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 21: 207-213.
334. O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, et al. (2010) Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sex Transm Dis 37: 100-104.
335. McGowan I, Gomez K, Bruder K, Febo I, Chen BA, et al. (2011) Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 25: 1057-1064.
336. Cohen CR, Brown J, Moscicki AB, Bukusi EA, Paull JR, et al. (2011) A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days. PLoS One 6: e16258.
337. Chen MY, Millwood IY, Wand H, Poynten M, Law M, et al. (2009) A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis. J Acquir Immune Defic Syndr 50: 375-380.
338. Choi Y, Yoshida T, Mimura T, Kaneko Y, Nakashima H, et al. (1996) Synthesis of sulfated octadecyl ribo-oligosaccharides with potent anti-AIDS virus activity by ring-opening polymerization of a 1,4-anhydroribose derivative. Carbohydr Res 282: 113-123.
339. Roy R, Zanini D, Meunier SJ, Romanowska A (1993) Solid-phase synthesis of dendritic sialoside inhibitors of influenza A virus haemagglutinin. J Chem Soc, Chem Commun 24: 1869-1872.
340. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, et al. (2000) Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 74: 1948-1960.
341. Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, et al. (2011) Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res 90: 195-199.
342. Vemuri S, Rhodes CT (1995) Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv 70: 95-111.
343. Joanna Rejman J, Oberle V, Zuhorn IS, Hoekstra D (2004) Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J 377: 159-169.
344. Long D, Berson JF, Cook DG, Doms RW (1994) Characterization of human immunodeficiency virus type 1 gp120 binding to liposomes containing galactosylceramide. J Virol 68: 5890-5898.
345. Konopka K, Davis BR, Larsen CE, Alford DR, Debs RJ, et al. (1990) Liposomes modulates human immunodeficiency virus infectivity. J Gen Virol 71: 2899-2907.
346. Larsen CE, Nir S, Alford DR, Jennings M, Lee KD, et al. (1993) Human immunodeficiency virus type 1 (HIV-1) fusion with model membranes: kinetic analysis and the role of lipid composition, pH and divalent cations. Biochim Biophys Acta 1147: 223-236.
347. Chonn A, Semple SC, Cullis PR (1992) Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 267: 18759-18765.
348. Oja CDM, Semple SC, Chonn A, Cullis PR (1996) Influence of dose on liposome clearance: critical role of blood proteins. Biochim Biophys Acta 1281: 31-37.
349. Malavia NK, Zurakowski D, Schroeder A, Princiotto AM, Laury AR, et al. (2011) Liposomes for HIV prophylaxis. Biomaterials 32: 8663-8668.
350. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D (1991) Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070: 187-192.
351. Needham D, McIntosh TJ, Lasic DD (1992) Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1108: 40-48.
352. Francis GE, Delgado C, Fisher D, Malik F, Agrawal AK (1996) Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J Drug Target 3: 321-340.
353. Kish-Catalone T, Pal R, Parrish J, Rose N, Hocker L, et al. (2007) Evaluation of-2 RANTES vaginal microbicide formulations in a nonhuman primate simian/ human immunodeficiency virus (SHIV) challenge model. AIDS Res Hum Retroviruses 23: 33-42.
354. Caron M, Besson G, Etenna SL, Mintsa-Ndong A, Mourtas S, et al. (2010) Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV. Virology 405: 225-233.
355. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160.
356. Chonn A, Cullis PR, Devine DV (1991) The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 146: 4234-4241.
357. Marjan J, Xie Z, Devine DV (1994) Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochim Biophys Acta 1192: 35-44.
358. Bradley AJ, Devine DV, Ansell SM, Janzen J, Brooks DE (1998) Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch Biochem Biophys 357: 185-194.
359. Price ME, Cornelius RM, Brash JL (2001) Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochim Biophys Acta 1512: 191-205.
360. Eccleston GM (1992) Microemulsion. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical technology. New York: Marcel Dekker, 375-421.
361. Klyashchitsky BA, Owen AJ (1998) Drug delivery systems for cyclosporine: achievements and complications. J Drug Target 5: 443-458.
362. Gasco MR, Gallarate M, Trotta M, Bauchiero L, Gremmo E, et al. (1989) Microemulsions as topical delivery vehicles: ocular administration of timolol. J Pharm Biomed Anal 7: 433-439.
363. Osborne DW, Ward AJ, O'Neill KJ (1991) Microemulsions as topical drug delivery vehicles: in-vitro transdermal studies of a model hydrophilic drug. J Pharm Pharmacol 43: 450-454.
364. Lawrence MJ (1994) Surfactant systems: microemulsions and vesicles as vehicles for drug delivery. Eur J Drug Metab Pharmacokinet 19: 257-269.
365. Al-Adham IS, Khalil E, Al-Hmoud ND, Kierans M, Collier PJ (2000) Microemulsions are membrane-active, antimicrobial, self-preserving systems. J Appl Microbiol 89: 32-39.
366. Lawrence MJ, Rees GD (2000) Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45: 89-121.
367. Tenjarla S (1999) Microemulsions: an overview, and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 16: 461-521.
368. D'Cruz OJ, Uckun FM (2001) Gel-microemulsions as vaginal spermicides and intravaginal drug delivery vehicles. Contraception 64: 113-123.
369. D'Cruz OJ, Yiv SH, Uckun FM (2001) GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion. AAPS PharmSciTech 2: E5.
370. D'Cruz OJ, Venkatachalam T, Zhu Z, Shih M, Uckun FM (1998) Aryl phosphate derivatives of bromo-methoxy-azidothymidine are dualfunction spermicides with potent anti-HIV activity. Biol Reprod 59: 503-515.
371. D'Cruz OJ, Shih MJ, Yiv SH, Chen CL, Uckun FM (1999) Synthesis, characterization and preclinical formulation of a dual-action phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07) with potent anti-HIV and spermicidal activities. Mol Hum Reprod 5: 421-432.
372. Uckun FM, D'Cruz OJ (1999) Prophylactic contraceptives for HIV/AIDS. Hum Reprod Update 5: 506-514.
373. D'Cruz OJ, Venkatachalam TK, Uckun FM (2000) Structural requirements for potent human spermicidal activity of dual-function aryl phosphate derivative of bromo-methoxy zidovudine (WHI-07). Biol Reprod 62: 37-44.
374. D'Cruz OJ, Uckun FM (2003) Contraceptive activity of a spermicidal aryl phosphate derivative of bromo-methoxy-zidovudine (compound WHI-07) in rabbits. Fertil Steril 79: 864-872.
375. D'Cruz OJ, Waurzyniak W, Uckun FM (2004) Antiretroviral spermicide WHI-07 prevents vaginal and rectal transmission of feline immunodeficiency virus in domestic cats. Antimicrob Agents Chemother 48: 1082-1088.
376. D'Cruz OJ, Venkatachalam TK, Uckun FM (2001) Thymidine kinaseindependent intracellular delivery of bioactive nucleotides by aryl phosphate derivatives of bromo-methoxy zidovudine (WHI-05 and WHI-07) in normal human female genital tract epithelial cells and sperm. Biol Reprod 64: 51-59.
377. D'Cruz OJ, Waurzyniak B, Yiv SH, Uckun FM (2000) Evaluation of subchronic (13-week) and reproductive toxicity potential of intravaginal gel-microemulsion formulation of a dual-function phenyl phosphate derivative of bromo-methoxy zidovudine (WHI-07) in B6C3F1 mice. J Appl Toxicol 20: 319-325.
378. D'Cruz OJ, Uckun FM (2001) Lack of adverse effects on fertility of female CD-1 mice exposed to repetitive intravaginal gel-microemulsion formulation of a dual-function anti-HIV agent: aryl phosphate derivative of bromo-methoxyzidovudine (compound WHI-07). J Appl Toxicol 21: 317-322.
379. D'Cruz OJ, Uckun FM (2001) Short-term (13-week) toxicity study of 5-bromo-6-methoxy-5,6-dihydro-3′-azidothymidine-5′-(p-bromophenyl) methoxyalaninyl phosphate (WHI-07), a novel anti-HIVand contraceptive agent, in B6C3F1 mice. Toxicol Sci 60: 373-378.
380. D'Cruz OJ, Erbeck D, Waurzyniak W, Uckun FM (2002) Two-year toxicity and carcinogenicity studies in B6C3F1 mice with 5-bromo-6-methoxy-5, 6-dihydro-3′-azidothymidine-5′-(p-bromophenyl) methoxy alaninyl phosphate (WHI-07), a novel anti-HIV and contraceptive agent. Toxicology 179: 61-67.
381. D'Cruz OJ, Erbeck D, Uckun FM (2003) Developmental toxicology studies of WHI-07, a novel nucleoside analogue-based dual-function microbicide, administered intravaginally to rabbits. Toxicol Pathol 31: 698-708.
382. D'Cruz OJ, Uckun FM (2008) Evaluation of local tolerance of the antiretroviral spermicide (WHI-07)-loaded gel-microemulsion in the porcine female reproductive tract. J Appl Toxicol 28: 303-314.
383. D'Cruz OJ, Uckun FM (2007) Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat. Toxicol Pathol 35: 910-927.
384. Mishell DR Jr (1993) Vaginal contraceptive rings. Ann Med 25: 191-197.
385. Nash HA, Alvarez-Sanchez F, Mishell DR Jr, Fraser IS, Maruo T, et al. (1999) Estradiol-delivering vaginal rings for hormone replacement therapy. Am J Obstet Gynecol 181: 1400-1406.
386. Barnhart KT, Timbers K, Pretorius ES, Lin K, Shaunik A (2005) In vivo assessment of NuvaRing placement. Contraception 72: 196-199.
387. Malcolm K, Woolfson D, Russell J, Tallon P, McAuley L, et al. (2003) Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release 90: 217-225.
388. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD (2005) Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal Rings. J Antimicrob Chemother 56: 954-956.
389. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD (2006) Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 325: 82-89.
390. Bell SE, Dennis AC, Fido LA, Malcolm RK, Sirimuthu NM, et al. (2007) Characterization of silicone elastomer vaginal rings containing HIV microbicide TMC120 by Raman spectroscopy. J Pharm Pharmacol 59: 203-207.
391. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ (2010) Advances in microbicide vaginal rings. Antiviral Res 88: S30-39.
392. Smith DJ, Wakasiaka S, Hoang TD, Bwayo JJ, Del Rio C, et al. (2008) An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J Womens Health (Larchmt) 17: 1025-1034.
393. Clark MR, Johnson TJ, McCabe RT, Clark JT, Tuitupou A, et al. (2012) A hotmelt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci 101: 576-587.
394. Szycher M (1988) Biostability of polyurethane elastomers: a critical review. J Biomater Appl 3: 297-402.
395. Wells JM, Mercenier A (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6: 349-362.
396. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, et al. (1999) Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 180: 1863-1868.
397. Vasquez A, Jakobsson T, Ahrne S, Forsum U, Molin G (2002) Vaginal lactobacillus flora of healthy Swedish women. J Clin Microbiol 40: 2746-2749.
398. Cummings JH, Macfarlane GT (1997) Colonic microflora: nutrition and health. Nutrition 13: 476-478.
399. Hyman RW, Fukushima M, Diamond L, Kumm J, Giudice LC, et al. (2005) Microbes on the human vaginal epithelium. Proc Natl Acad Sci U S A 102: 7952-7957.
400. Boskey ER, Cone RA, Whaley KJ, Moench TR (2001) Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 16: 1809-1813.
401. Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutsky LA, et al. (1996) Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 174: 1058-1063.
402. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, et al. (1998) Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12: 1699-1706.
403. Chang TL, Chang CH, Simpson DA, Xu Q, Martin PK, et al. (2003) Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A 100: 11672-11677.
404. Fredricks DN, Fiedler TL, Marrazzo JM (2005) Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 353: 1899-1911.
405. Spear GT, Gilbert D, Landay AL, Zariffard R, French AL, et al. (2011) Pyrosequencing of the genital microbiotas of HIV-seropositive and-seronegative women reveals Lactobacillus iners as the predominant Lactobacillus species. Appl Environ Microbiol 77: 378-381.
406. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, et al. (2006) Metagenomic analysis of the human distal gut microbiotome. Science 312: 1355-1359.
407. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59-65.
408. Momozawa Y, Deffontaine V, Louis E, Medrano JF (2011) Characterization of bacteria in biopsies of colon and stools by high throughput sequencing of the V2 region of bacterial 16S rRNA gene in human. PLoS ONE 6: e16952.
409. Liu X, Lagenaur LA, Lee PP, Xu Q (2008) Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl Environ Microbiol 74: 4626-4635.
410. Pusch O, Kalyanaraman R, Tucker LD, Wells JM, Ramratnam B, et al. (2006) An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 20: 1917-1922.
411. Liu JJ, Reid G, Jiang Y, Turner MS, Tsai CC (2007) Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14. Cell Microbiol 9: 120-130.
412. Rao S, Hu S, McHugh L, Lueders K, Henry K, et al. (2005) Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci U S A 102: 11993-11998.
413. Chancey CJ, Khanna KV, Seegers JF, Zhang GW, Hildreth J, et al. (2006) Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. J Immunol 176: 5627-5636.
414. Pusch O, Boden D, Hannify S, Lee F, Tucker LD, et al. (2005) Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J Acquir Immune Defic Syndr 40: 512-520.
415. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, et al. (2011) Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 4: 648-657.